Article | July 31, 2020

Key Considerations For Cryogenic Preservation And T-Cell Viability

Source: Cytiva
Cytiva-11

Discerning fact from fiction when freezing T cells for cell therapies.

Cryopreservation provides critical protection for cell therapies by minimizing genetic changes. But cooling too slowly or quickly risks diminishing cell viability upon thaw. On 11 March 2020, Cytiva’s Peter Kilbride (senior research scientist) and Julie Meneghel (cryobiologist) discussed the importance of controlled-rate cryopreservation. Illustrating how mammalian cells change when frozen, they offered concrete cryopreservation strategies and identified temperatures at which it is safe to stop controlled cooling and transfer drug product to cryogenic storage.

access the Article!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Biosimilar Development? Subscribe today.

Subscribe to Biosimilar Development X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.

or

Subscribe to Biosimilar Development